Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioGeneriX and Neose report positive neutropenia data
The first Phase I study evaluated a randomized, weight-based, single ascending dose of GlycoPEG-GCSF compared to Neulasta in 53 healthy subjects. This trial shows that single doses of
The first Phase I study evaluated a randomized, weight-based, single ascending dose of GlycoPEG-GCSF compared to Neulasta in 53 healthy subjects. This trial shows that single doses of
Nastech will immediately advance Teriparatide (PTH1-34) nasal spray into a Phase II clinical study to evaluate the change in bone mineral density, which the FDA has previously indicated
The new BCM MRSA ELF culture media will be manufactured and sold by Biosynth under license from Invitrogen’s molecular probes business. BCM MRSA ELF is designed to provide
Strong activity was observed in the Phase I clinical trial consisting of 40 patients with advanced solid tumors. AV-951 was also found to be well tolerated. Of the
This project is part of a contract awarded in 2005 by the US Department of Health and Human Services (HHS) for the development of a new cell culture-
The final 12-month data confirm the trends seen in the previous data at six and nine months for both smoking cessation and long-term smoking abstinence. Importantly, there was
Advanced Cell Technology (ACT) had already published 6-month data for the trial. The trial also showed evidence that the hearts of the patients that received the therapy showed
Results from the COMET (combination of Mmthotrexate and etanercept in active early rheumatoid arthritis) trial will be presented at the American College of Rheumatology (ACR) scientific meeting in
In an oral presentation entitled “A Phase II trial of KRX-0401 (perifosine) in patients with chemo-insensitive sarcomas: preliminary results,” Dr Joseph Ludwig assistant professor, dept of sarcoma, MD
In July, 2006, Ono and Locus entered into a drug discovery agreement targeting a kinase selected by Ono with the goal of identifying small molecule inhibitors of the